Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
Completed · Phase 1
Conditions studied: Non-alcoholic Fatty Liver Disease
In brief
The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with hepatic impairment. The results of this study will support treatment and dosing decisions for patients with varying degrees of hepatic impairment.
Key facts
- Study ID
- NCT03681457
- Run by
- Novartis Pharmaceuticals
- People needed
- 42
- Starts
- 2018-09-24
- Expected to finish
- 2019-09-25
- Last updated by the study team
- 2020-12-14
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- In good health as determined by past medical history, physical examination, ECG, laboratory tests, and urinalysis at Screening.
- Exclusion Criteria:
- Liver disease or liver injury
- Chronic infection with Hepatitis B or Hepatitis C
- History or presence of impaired renal function
- Hepatically Impaired Subjects:
- Inclusion Criteria:
- Hepatic impairment as defined by the Child-Pugh classification for severity of liver disease
- Exclusion Criteria:
- Severe complications of liver disease within the preceding 3 months
- Emergency room visit or hospitalization due to liver disease within the preceding 3 months for mildly and moderately hepatically impaired subjects, and within the preceding 1 month for severely hepatically impaired subjects
- Subject has received liver transplant at any time in the past and is on immunosuppressant therapy
- Acute Hepatitis B or Hepatitis C infection
- Other protocol-defined inclusion/exclusion criteria may apply.
You may not qualify if…
- Use of other study drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
- History of hypersensitivity to the study treatment or to drugs of similar chemical classes
- Pregnant or nursing women
- Women of child-bearing potential
- Healthy Volunteers:
- Inclusion Criteria:
- In good health as determined by past medical history, physical examination, ECG, laboratory tests, and urinalysis at Screening.
- Exclusion Criteria:
- Liver disease or liver injury
- Chronic infection with Hepatitis B or Hepatitis C
- History or presence of impaired renal function
- Hepatically Impaired Subjects:
- Inclusion Criteria:
- Hepatic impairment as defined by the Child-Pugh classification for severity of liver disease
- Exclusion Criteria:
- Severe complications of liver disease within the preceding 3 months
- Emergency room visit or hospitalization due to liver disease within the preceding 3 months for mildly and moderately hepatically impaired subjects, and within the preceding 1 month for severely hepatically impaired subjects
- Subject has received liver transplant at any time in the past and is on immunosuppressant therapy
- Acute Hepatitis B or Hepatitis C infection
- Other protocol-defined inclusion/exclusion criteria may apply.
Where it is running
- Novartis Investigative Site — Orlando, Florida, United States
- Novartis Investigative Site — Orlando, Florida, United States
- Novartis Investigative Site — Knoxville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.